ATE542535T1 - Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten - Google Patents

Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten

Info

Publication number
ATE542535T1
ATE542535T1 AT06724715T AT06724715T ATE542535T1 AT E542535 T1 ATE542535 T1 AT E542535T1 AT 06724715 T AT06724715 T AT 06724715T AT 06724715 T AT06724715 T AT 06724715T AT E542535 T1 ATE542535 T1 AT E542535T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
azapaullone
autoimmune diseases
pancreatic autoimmune
Prior art date
Application number
AT06724715T
Other languages
English (en)
Inventor
Rainer Mussmann
Conrad Kunick
Hendrik Stukenbrock
Marcus Geese
Simone Kegel
Ulrike Burk
Original Assignee
Develogen Ag
Tech Uni Carolo Wilhelmina Zu Braunschweig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Tech Uni Carolo Wilhelmina Zu Braunschweig filed Critical Develogen Ag
Application granted granted Critical
Publication of ATE542535T1 publication Critical patent/ATE542535T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06724715T 2005-05-04 2006-05-04 Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten ATE542535T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05009846 2005-05-04
EP05015986 2005-07-22
EP05023168 2005-10-24
EP06001327 2006-01-23
PCT/EP2006/004186 WO2006117221A1 (en) 2005-05-04 2006-05-04 Use of azapaullones for preventing and treating pancreatic autoimmune disorders

Publications (1)

Publication Number Publication Date
ATE542535T1 true ATE542535T1 (de) 2012-02-15

Family

ID=36625260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06724715T ATE542535T1 (de) 2005-05-04 2006-05-04 Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten

Country Status (4)

Country Link
US (1) US7968535B2 (de)
EP (1) EP1879591B8 (de)
AT (1) ATE542535T1 (de)
WO (1) WO2006117221A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907122B8 (pt) 2008-01-11 2021-05-25 Albany Molecular Res Inc compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
EP3026052A1 (de) 2009-04-20 2016-06-01 Auspex Pharmaceuticals, Inc. Vobereitung von deuterierte piperidinhemmer der janus-kinase 3
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
EP2654767A4 (de) 2010-12-22 2014-05-21 Amylin Pharmaceuticals Inc Glp-1-rezeptoragonisten zur inselzelltransplantation
EP3920885A1 (de) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproinsäureverbindungen und wnt-agonisten zur behandlung von ohrerkrankungen
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804959B1 (fr) * 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
DE10290025T1 (de) 2001-04-19 2003-10-09 Develogen Ag Verfahren zur Differenzierung von Stammzellen in Insulin-produzierende Zellen
MXPA04000906A (es) * 2001-08-03 2004-11-22 Novo Nordisk As Nuevos derivados de 2,4-diaminotiazol.
CA2477117A1 (en) 2002-02-22 2003-08-28 Teijin Limited Pyrrolopyrimidine derivative
CA2477967C (en) * 2002-03-05 2010-08-10 Eli Lilly And Company Purine derivatives as kinase inhibitors
US8048454B2 (en) * 2004-03-09 2011-11-01 Michael Martin Methods and compositions related to regulation of cytokine production by glycogen synthase kinase 3 (GSK-3)
WO2005104836A2 (en) * 2004-04-16 2005-11-10 Albert Einstein College Of Medicine Of Yeshiva University Drosophila models for diseases affecting learning and memory

Also Published As

Publication number Publication date
US7968535B2 (en) 2011-06-28
US20080287423A1 (en) 2008-11-20
EP1879591A1 (de) 2008-01-23
WO2006117221A1 (en) 2006-11-09
EP1879591B1 (de) 2012-01-25
EP1879591B8 (de) 2012-04-04

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2007009807A (es) Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento.
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
TW200716140A (en) Treatment of inflammatory conditions
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
ATE521608T1 (de) Glucokinaseaktivatoren
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
DE602006008643D1 (de) Ophthalmische Zusammensetzungen von parasympathischen Stimulantia und Entzündungshemmer zur Verwendung bei der Behandlung von Presbyopie
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
IN2012DN02471A (de)
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2009009417A3 (en) Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
EP1879591B8 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
TW200716132A (en) Novel chemical compounds